Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Serhat Seyhan

Serhat Seyhan

Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Turkey

Title: Correlation between Expressions of IL-3, IL-6 and IL-11 Genes and Chronic Myeloid Leukemia

Biography

Biography: Serhat Seyhan

Abstract

Statement of the Problem:

Chronic myeloid leukemia (CML) is a hematopoietic malignancy originating from transformation of a hematopoietic stem cell. BCR-ABL gene that resulted from a translocation between chromosomes 9 and 22 is detected in the majority of CML patients. IL-3, IL-6 and IL-11 are cytokines that affects the development of myeloid cells. The aim of this study to evaluate the relationship between IL-3, IL-6 and IL-11 and CML development.

Methodology & Theoretical Orientation: This study was perfomed using peripheral blood from 33 patients followed in our hematology clinic at Karadeniz Technical University Medical School obtained with a diagnosis of CML. We get peripheral blood from 34 healthy people that examined in Karadeniz Technical University Medical Schools clinics. RNA was isolated from peripheral blood and cDNA is synthesized. Then cDNA expression analysis was performed. Findings: IL-3, IL-6 and IL-11 gene expressions significantly decreased in CML patients with high expression of BCR-ABL gene compared to healthy individuals. After major molecular response IL-3, IL-6 and IL-11 gene expressions increased compared with the initial diagnosis of CML.

Conclusion & Significance: According to the our results; increase of BCR-ABL gene expression in CML patients may provide the proliferation of neoplastic cells without effective IL-3, IL-6 and IL-11 gene expressions in normal hematopoiesis. Ä°nverse relationship in our CML patients are available between BCR-ABL expression and IL-3, IL-6 and IL-11 expressions. Studies for IL-3, IL-6 and IL-11 gene expressions are needed to determine the relationship with BCR-ABL expression level and to be used follow up of patients with CML

Recent Publications (minimum 5)

  1. Pehlivan M, Sahin HH, Pehlivan S, Ozdilli K, Kaynar L, Oguz FS (2014) Prognostic importance of single-nucleotide polymorphisms in IL-6, IL-10, TGF-beta1, IFN-gamma, and TNF-alpha genes in chronic phase chronic myeloid leukemia. Genetic testing and molecular biomarkers 18 (6):403-9.
  2. Welner RS, Amabile G, Bararia D, Czibere A, Yang H, Zhang H (2015) Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer cell 27 (5):671-81.
  3. Apperley JF (2015) Chronic myeloid leukaemia. Lancet 385 (9976):1447-59.
  4. Shet AS, Jahagirdar BN, Verfaillie CM (2002) Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 16 (8):1402-11.
  5. Ren R (2002) The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene 21 (56):8629-42.
  6. Melo JV, Deininger MW (2004) Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation. Hematology/oncology clinics of North America 18 (3):545-68, vii-viii.